ALK/ATR combination therapy is effective in neuroblastoma mo…

Emerging


1
Citations
46
Refs
2025
Year
Search Works
Work Details
  • DOI 10.1101/2025.07.17.665300
  • OpenAlex ID W4412526905
  • Type Preprint
  • Language EN
  • Published 21 Jul 2025
  • Source bioRxiv (Cold Spring Harbor Laboratory)
  • Publisher Cold Spring Harbor Laboratory
  • Countries 2
  • Institutions 3
  • Added 10 Oct 2025
  • Updated 04 Oct 2026
MENU
0

ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCN

Preprint 2025 EN Green

Summary paragraph One of the key features of high-risk neuroblastoma (NB) is MYCN -amplification. While MYCN is still regarded as therapeutically challenging despite intensive efforts to find targeting compounds, inhibitors against Anaplastic Lymphoma Kinase (ALK) are now being evaluated among ALK-driven NB patients with promising results. There is a pressing need to find alternative treatment reg…

1

Citations

46

References

12

Authors

0.00

FWCI

Citations by Year
Last 1 years
Topics
Keywords
UN Sustainable Development Goals
1 SDGs
Authors & Affiliations
12 authors
#AuthorInstitutionsORCID
1 Marcus Borenäs University of Gothenburg (SE)
2 Dan Emil Lind University of Gothenburg (SE)
3 Adam Lehnberg University of Gothenburg (SE) —
4 Edit Zenténius University of Gothenburg (SE) —
5 Matilda Esselius University of Gothenburg (SE) —
6 Eva Jennische University of Gothenburg (SE)
7 Joel Johansson University of Gothenburg (SE) —
8 Jikui Guan University of Gothenburg (SE)
9 Agata Aniszewska University of Gothenburg (SE)
10 Jimmy Van den Eynden Ghent University (BE) Cancer Research Institute Ghen… (BE)
11 Bengt Hallberg University of Gothenburg (SE)
12 Ruth Helen Palmer Corresponding University of Gothenburg (SE)

Data: OpenAlex